Current Size: 100%



The LBG Meeting for Health Sciences encourages and supports young scientists by offering them an opportunity to present their work. Moreover, it is a chance for early career researchers to establish themselves within the scientific setting. The conference focuses on the translation of research results from theory into practice. Therefore, abstracts on preclinical, clinical or implementation research are welcome. The thematic sessions will include key-note lectures by international experts and oral presentations of the best submitted abstracts.

+++ Call for abstracts now open! +++

Afatinib might be rational treatment for many lung cancer patients

Lung cancer remains a serious health threat with less than one in five patients still alive 5 years after diagnosis. This is mainly due to the lack of modern treatment options for the majority of patients, which still receive classical chemotherapy. However, Emilio Casanova and Herwig Moll from the Ludwig Boltzmann Institute of Cancer Research (LBI-CR) and Medical University of Vienna (MUV) now describe in the journal Science Translational Medicine that the established drug Afatinib may prove an unexpected therapeutic option for many patients.

New paper on Targeting STAT5B in T-Cell Neoplasia.

STAT5BN642H-driven proliferation in T-cell leukemia/lymphoma via common γ-chain (γc)-receptor signaling. STAT5BN642H is activated by Janus kinase (JAK) upon cytokine stimulation such as interleukin 2 (IL-2). Subsequently, phosphorylated STAT5BN642H translocates into the nucleus and initiates transcription. (1) STAT5BN642H exhibits prolonged activation and enhanced DNA binding leading to (2) increased transcription of STAT5 target genes and enhanced proliferation.

The somatic hot spot mutation in STAT5B was found in many T cell leukemia/lymphoma patients. The team of  Moriggl generated and analyzed a transgenic mouse model with hematopoietic STAT5BN642H expression that caused aggressive T-cell leukemia/lymphomas. Herein, we discuss the scientific merit of our model and its relevance for pre-clinical studies.

Now published in Molecular & Cellular Oncology Volume 5, 2018 - Issue 3


Molecular imaging and molecular diagnostics: two sides of the same coin?

Today we are rapidly entering the age of personalized medicine, which means that molecular diagnostic techniques are increasingly used for the guidance of individualized therapy and the prediction of treatment response. As a consequence, the clinical field of pathology is today increasingly converting into a field of molecular pathology strategy.

A New Achilles’ Heel of Blood Cancer

AML cell lines containing MLL fusion proteins display many immature cells © CeMM/Anna Skucha

Acute Myeloid Leukemia (AML) is an aggressive form of blood cancer that frequently develops in children. The diseased cells often carry mutated forms of a specific gene, which is known to function within large protein networks. Applying a combination of highthroughput proteomic and genomic screens in AML cells, researchers at CeMM and LBI-CR identified a protein of this network crucial for the survival of the cancer cells.

Conclusion Meeting in Seggau presents highlights of cancer research

We are grateful to our partners and sponsors for enabling an impressive scientific programme with many outstanding international colleagues. The presentations included updates about tumour surveillance, new therapeutics and super enhancers. We had many fruitful discussions and due to the generosity of the sponsors we could include many junior researchers to participate in this meeting. Joining into scientific discussions with leaders in their field of research will foster their scientific education.

Annual Meeting in Seggau

The team leaders of the LBI-CR welcome many leading cancer researchers in Seggau (image: courtesy P. Look)

From Receptors and Kinases to Transcriptional Regulators: Cancer Genome Landscapes and their Therapeutic Targets

On May 6 many cancer researchers converge to Seggau Castle for a final meeting of the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) within a historic landscape. 

Molecular drivers of Tasmanian devil facial tumor disease revealed

The Tasmanian devil faces extinction due to devil facial tumor disease (DFTD), which is transmitted between individuals by bites during fighting. Cancer cells do not usually transmit between individuals. To unveil the molecular underpinnings of DFTD, we designed an approach that combines sensitivity to drugs with an integrated systems-biology characterization. Sensitivity to inhibitors of the ERBB family of receptor tyrosine kinases correlated with their overexpression, suggesting a causative link.